The Company will accelerate the commercial deployment of its Artificial Intelligence reading solution for 2D/3D mammography, with a focus on the United States. Therapixel, designer and supplier of MammoScreen an Artificial Intelligence software reading aid for mammography, announces today a 15 M€ financing round in series B.

Therapixel, designer and supplier of MammoScreen an Artificial Intelligence software reading aid for mammography, announces today a 15 M€ financing round in series B. This operation was led by Crédit Mutuel Innovation and CapHorn, joined by Verve, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement. This fundraising will enable Therapixel to accelerate its commercial presence in the United States, launch more unique features for MammoScreen, and push even further the boundaries of its intelligent reading aid for mammography.

Armed with two FDA regulatory clearances in the United States for both 2D and 3D (tomosynthesis) mammography, MammoScreen is already being deployed across large networks of breast cancer screening clinics. MammoScreen uses a unique score, MammoScreen Score™ to signal at a glance the level of suspicion of a mammogram. This makes it possible to confirm the lesions that are certain and to save precious time with a faster reading of benign cases. Radiologists can thus feel more confident in their decision and spend more time on difficult cases that require more attention.

Matthieu Leclerc-Chalvet, Chief Executive Officer of Therapixel states: “We are very satisfied to close this new round of financing with investors active in the field of digital health. These funds will allow us to grow our American team with new sales and support people and to ramp up our commercial activities. With an already strong pipeline, Therapixel is poised for significant growth and will have a decisive impact on breast cancer screening.

Pierre Fillard, Chief Scientific and Technology Officer and Founder of Therapixel continues: “This is a major step for Therapixel and I am proud of the achievements of our teams in collaboration with radiologists partners. We will accelerate the launch of a new generation of AI that will allow women to benefit from an earlier detection with less anxiety and radiologists to be assisted in the ever-growing demand for imaging. We will also advance the regulatory and clinical developments that will solidify our leading position as the AI solution of choice for radiologists reading mammography.

Jérôme Féraud, Director of healthcare investments and Tanguy Besson, Associate at Crédit Mutuel Innovation, continue: “Beyond the technological performance of the solutions developed by Therapixel, it became obvious for us to support the deployment of MammoScreen that helps improve breast cancer detection, at a time when women are in a particularly stressful situation. The overall ergonomic of the solution brings the radiologists a valuable image analysis tool that allow them to optimize their time and focus their expertise on the specifics of the case.

François Santi, Principal at CapHorn continues: “We are very pleased to support Therapixel in this new round of strategic investment, in collaboration with several experienced investors in the field of digital health. We followed Therapixel for several months and were impressed by the capability of execution of the team and their achievements during this period. We are very happy to support Therapixel’s commercial expansion in the United States, and help the company establish a new standard in breast cancer detection.

With this new round, Therapixel has raised more than 20 M€ since its founding in 2013.

  • Crédit Mutuel Innovation
  • Tanguy Besson
    +33 (0)1 44 50 29 81
  • Jerôme Feraud
    Director of healthcare investments
  • Matthieu Leclerc-Chalvet,
  • Pierre Fillard,
    Chief Scientific and Technology Officer
  • Advisors
  • Legal counsel: JonesDay – Renaud Bonnet
  • Financial advisors: Fraser Finance – Olivier Koechlin and Deborah Herst

Contact us